Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Rongzhe LiuOlalekan O OluwoleIbrahim DiakiteMarc F BottemanJulia Thornton SniderFrederick L LockePublished in: Journal of medical economics (2021)
In this simulation, axi-cel was a superior treatment option as it is predicted to achieve better outcomes at lower or minimal incremental costs versus tisa-cel.